ArticleProceedings of the National Academy of Sciences of the United States of America1996
Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 136 citations in OpenAlex.
- Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53.Translational oncology · 2025Article
- High CD133 expression in proximal tubular cells in diabetic kidney disease: good or bad?Journal of translational medicine · 2024Article
- Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?Cell death and differentiation · 2022Review
- Identification of optimal reference genes for gene expression normalization in human osteosarcoma cell lines under proliferative conditions.Frontiers in genetics · 2022Article
- Association of p53 with Neurodegeneration in Parkinson's Disease.Parkinson's disease · 2022Review
- Census and evaluation of p53 target genes.Oncogene · 2017Review
- P53 at the start of the 21st century: lessons from elephants.F1000Research · 2017Review
- Article
- Expression of p53 target genes in the early phase of long-term potentiation in the rat hippocampal CA1 area.Neural plasticity · 2015Article
- The transcription factor p53: not a repressor, solely an activator.Cell cycle (Georgetown, Tex.) · 2014Article
- Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.The American journal of pathology · 2013Article
- Article
- The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation.Cancer biology & therapy · 2012Article
- Article
- The antagonism between MCT-1 and p53 affects the tumorigenic outcomes.Molecular cancer · 2010Article
- Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Discovery of novel tumor suppressor p53 response elements using information theory.Nucleic acids research · 2008Article
- Two estrogen response element sequences near the PCNA gene are not responsible for its estrogen-enhanced expression in MCF7 cells.PloS one · 2008Article
- Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.World journal of gastroenterology · 2005Article
- Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity.Retrovirology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Proliferating-cell nuclear antigen (PCNA) is a DNA damage-inducible protein that performs an essential function in DNA replication and repair as an auxiliary factor for DNA polymerases delta and epsilon. Examination of the human PCNA promoter DNA sequence revealed a site with homology to the consensus DNA sequence bound by p53. PCNA promoter fragments with this site intact bound p53 in vitro and were transcriptionally activated by wild-type p53 in transient expression assays in SAOS-2 cells. The resident p53-binding site could be functionally substituted by a previously described p53-binding site from the ribosomal gene cluster. A plasmid expressing a mutated version of p53 derived from a patient with Li-Fraumeni syndrome failed to activate the PCNA promoter in the cotransfection assay. In different cell types, activation of the PCNA promoter by the p53-binding sequence correlated with the status of p53. Activation of the PCNA promoter by wild-type p53 depends upon the level of p53 expression. This concentration dependence and cell type specificity reconciles the observations presented here with prior results indicating that wild-type p53 represses the PCNA promoter. These findings provide a mechanism whereby p53 modulates activation of PCNA expression as a cellular response to DNA damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.